ABL partners with our clients to develop and optimize the downstream conditions necessary to deliver high yields of stable therapeutic and vaccine products. ABL will pull upon past experience, and a knowledge of best practices in the field to deliver a process that meets the necessary production, quality, and regulatory requirements of the product. Our downstream development goal is to use purification technologies that are commercially available, cost effective, and will meet product specifications for quantity, purity and potency. Upon completion of every process development program ABL provides a detailed report explaining the different scenarios that were attempted and along with the final process.
Services
Downstream purification optimization
Development and validation of viral inactivation unit operations
Process scale-up
Cost of goods analysis
Capabilities
Akta Process skid
Akta Pilot skid
Experience
Recombinant proteins
Antibodies
Fusion Proteins
Vaccines
Viral vectors
To discuss your project requirements from cell line development to cell banking to cGMP production of your biologic product, please call or email:
